Details of the Drug Combination

General Information of Drug Combination (ID: DCR1TYB)

Drug Combination Name
Naloxegol Ketoconazole
Indication
Disease Entry Status REF
Bioavailability Phase 1 [1]
Component Drugs Naloxegol   DML0B41 Ketoconazole   DMPZI3Q
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Naloxegol
Disease Entry ICD 11 Status REF
Opioid-induced constipation DB32.1 Approved [2]
Naloxegol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Naloxegol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Naloxegol Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Ketoconazole
Disease Entry ICD 11 Status REF
Blastomycosis 1F22 Approved [3]
Chromomycosis N.A. Approved [3]
Coccidioidomycosis 1F25 Approved [3]
Cutaneous candidiasis 1F23.14 Approved [3]
Fungal infection 1F29-1F2F Approved [4]
Histoplasmosis N.A. Approved [3]
Invasive candidiasis 1F23 Approved [3]
Mycoses 1F2Z Approved [3]
Oral candidiasis 1F23.0 Approved [3]
Paracoccidioidomycosis N.A. Approved [3]
Pityriasis simplex N.A. Approved [3]
Prostate adenocarcinoma N.A. Approved [3]
Tinea corporis 1F28.Y Approved [3]
Tinea cruris 1F28.3 Approved [3]
Tinea versicolor 1F2D.0 Approved [3]
Tinea pedis 1F28.2 Investigative [3]
Ketoconazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Inhibitor [8]
------------------------------------------------------------------------------------
Ketoconazole Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Ketoconazole Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Ketoconazole Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases ADR [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01520896) Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7539).
3 Ketoconazole FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2568).
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
7 Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5.
8 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.